National Eye Institute (NEI)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Eye Institute (NEI) sits in the top decile of US sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count).

221 total trials 18 currently recruiting 179 completed early-phase tilt top decile by trial count

National Eye Institute (NEI): 221 sponsored US clinical trials, 18 recruiting.

National Eye Institute (NEI) sponsors 221 registered US clinical trials on ClinicalTrials.gov, 18 of them currently recruiting, and 179 completed. 11 of these trials are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Age-related Macular Degeneration, with 8 trials.

Top-decile sponsor footprint

National Eye Institute (NEI) ranks in the top decile of sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 68/100

179 of 196 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

221 total, page 2 of 5

COMPLETED Phase 1

Gevokizumab for Active Scleritis

NCT01835132
COMPLETED

AMD Phenotype and Genotype Study

NCT01778491
COMPLETED Phase 1

CNTF Implants for CNGB3 Achromatopsia

NCT01648452
COMPLETED Phase 2

Ranibizumab and Bevacizumab for Diabetic Macular Edema

NCT01610557
TERMINATED Phase 2

Finasteride for Chronic Central Serous Chorioretinopathy

NCT01585441
COMPLETED Phase 1

Minocycline to Treat Branch Retinal Vein Occlusion

NCT01468831
COMPLETED

Blood and Saliva Sample Collection for AREDS 2

NCT01553474
TERMINATED Phase 2

Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy

NCT01675947
COMPLETED Phase 1

Sirolimus Injections for Autoimmune Scleritis

NCT01517074
COMPLETED Phase 1

Minocycline to Treat Central Retinal Vein Occlusion

NCT01468844
COMPLETED Phase 1

Topical Interferon Gamma-1b for Central Serous Chorioretinopathy

NCT01468337
COMPLETED Phase 1

Sirolimus for Advanced Age-Related Macular Degeneration

NCT01445548
COMPLETED Phase 1

Dextromethorphan for Diabetic Macular Edema

NCT01441102
COMPLETED Phase 1

Topical Interferon Gamma for Macular Edema Secondary to Uveitis

NCT01376362
COMPLETED

The Natural History of Graft-Versus-Host Disease in the Eyes

NCT01369914
TERMINATED Phase 1

Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate

NCT01314417
COMPLETED Phase 1

Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration

NCT01271270
COMPLETED Phase 1

Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy

NCT01227993
COMPLETED Phase 1

Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis

NCT01195948
TERMINATED

Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema

NCT01168258
TERMINATED

Immunogenetic Mechanisms in Behcet's Disease

NCT01109433
COMPLETED Phase 1

A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema

NCT01120899
COMPLETED Phase 1

Rituximab for Autoimmune Retinopathy

NCT01086631
TERMINATED

Internal Monitoring of Eye Movement in Schizophrenia

NCT01011101
COMPLETED Phase 1

The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma

NCT00943982
COMPLETED Phase 1

Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti

NCT00876434
COMPLETED Phase 1

Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy

NCT00837252
COMPLETED Phase 1

Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD

NCT00766649
COMPLETED Phase 1

Sirolimus to Treat Diabetic Macular Edema

NCT00711490
COMPLETED

Evaluation and Treatment of People With Eye Diseases

NCT00708955
COMPLETED Phase 1

Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth

NCT00685854
COMPLETED Phase 1

Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth

NCT00685503
COMPLETED

Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires

NCT00678860
TERMINATED Phase 1

Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

NCT00673816
COMPLETED

High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration

NCT00656903
COMPLETED

Genetics and Markers of Degenerative and Inflammatory Eye Diseases

NCT00647439
COMPLETED

Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab

NCT00605943
TERMINATED

Visual Motor Coordination

NCT00568243
COMPLETED

Potential Research Participants for Future Studies of Inherited Eye Diseases

NCT00559234
TERMINATED

Human Samples and Data Repository

NCT00539370
COMPLETED

Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure

NCT00471731
COMPLETED Phase 1

Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation

NCT00457067
COMPLETED Phase 1

Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation

NCT00457145
COMPLETED

The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

NCT00331331
TERMINATED Phase 2

TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

NCT00464347
COMPLETED

Longitudinal Evaluation of Silicone Hydrogel (LASH) Study

NCT00727402
COMPLETED Phase 2

Metabolic Mapping to Measure Retinal Metabolism

NCT00385333
COMPLETED

Repository for Inherited Eye Diseases

NCT00378742
COMPLETED

Eye and Immunogenetic Features of Sarcoidosis

NCT00379275
COMPLETED Phase 3

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
← Previous Page 2 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 62
Phase 2 24
Phase 3 11

Therapeutic Areas

Age-related Macular Degeneration 8
Uveitis 6
Macular Degeneration 5
Retinal Degeneration 5
Diabetic Retinopathy 4
Retinitis Pigmentosa 4
Eye Diseases 4
Cataract 4
Retinal Vein Occlusion 3
Immunosuppression 3

What is open in the National Eye Institute (NEI) pipeline

18 recruiting of 221 indexed (8% open); 179 completed (81%).

Phase mix: 11 late (III/IV) vs 86 early (I/II) (early-phase heavy).

Top condition: Age-related Macular Degeneration (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Eye Institute (NEI): open-pipeline peers nationwide

Peers matched on 221 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

National Eye Institute (NEI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200250 0%5%10%15%20%25% Total trials Recruiting share National Eye Institute (NEI)Otsuka Pharmaceutical Development & CommercializationFlorida State UniversityPenn State UniversityUniversity of LouisvilleGE HealthcareHealthPartners InstituteOregon Research InstituteArcutis Biotherapeutics
National Eye Institute (NEI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Eye Institute (NEI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 221 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this National Eye Institute (NEI) page

221 registered trials is a research-attention snapshot, not an endorsement of National Eye Institute (NEI) or any single study.

  • 18 of National Eye Institute (NEI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Age-related Macular Degeneration is the condition National Eye Institute (NEI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Age-related Macular Degeneration trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Eye Institute (NEI) pipeline card: 221 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.